今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

中国水业集团宣布胡斯云退任执行董事，丘娜女士亦辞任独立非执行董事

香港，2024年6月18日 - 中国水业集团有限公司（股份代号：01129）今日宣布，胡斯云先生因其担任执行董事及丘娜女士担任独立非执行董事的决议案未获股东大会通过，根据公司组织章程细则规定，胡先生及丘女士已分别于股东大会结束后退任相关职务。

胡斯云先生自2000年4月起加入中国水业集团，曾担任多个重要职务，包括执行董事、副总经理、首席财务官等。在任职期间，胡先生为公司发展做出了重大贡献，带领公司实现了业务的快速增长和盈利能力的显著提升。

丘娜女士自2019年1月起担任中国水业集团独立非执行董事。她拥有丰富的财务和会计专业知识，曾担任多家上市公司独立董事职务。丘女士在任职期间，为公司治理和财务管控等方面提出了宝贵意见和建议。

中国水业集团董事会感谢胡斯云先生和丘娜女士为公司所做的贡献，并祝愿他们未来一切顺利。

关于中国水业集团

中国水业集团有限公司是一家领先的综合水务解决方案供应商，致力于为全球客户提供水处理、污水处理、海水淡化、水资源管理等领域的专业服务和技术解决方案。公司业务遍及全球多个国家和地区，拥有强大的技术研发实力和丰富的项目运营经验。

联系方式

中国水业集团有限公司

电话：+852 2893 1818

[移除了电子邮件地址]

网站：http://www.chinawatergroup.com/eng/